

# Corporate Fact Sheet



## Who We Are

Advanced BioHealing, Inc. (ABH) is a leader in commercializing the promise of regenerative medicine. The Company develops and commercializes living cell therapies that repair damaged human tissue and enable the body to heal itself. ABH currently manufactures and markets Dermagraft®, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. Dermagraft is FDA approved to treat diabetic foot ulcers and is the focus of an ongoing pivotal trial to assess the product's safety and efficacy in the promotion of healing venous leg ulcers.

## Company Milestones

- 2003** Advanced BioHealing founded
- 2004** Completed Series A financing
- 2005** Raised \$8 million Series B financing
- 2006** Acquired global rights to Dermagraft, TransCyte and Manufacturing Facilities in La Jolla, CA
- 2007** Launched Dermagraft in United States; secured \$30 million Series C financing
- 2008** Exceeded previous annual record of patients treated with Dermagraft; surpassed 150 full-time employees
- 2009** Initiated pivotal trial for venous leg ulcers (DEVO); initiated orthopedic soft tissue repair research program; surpassed 100,000 pieces of ABH-manufactured Dermagraft shipped
- 2010** Exceeded 300 full-time employees; as of June 30, achieved greater than 50% enrollment in DEVO trial

## Executive Management

- Kevin Rakin** Chairman & Chief Executive Officer
- Dean Tozer** Senior VP
- Keith O'Briant** Senior VP, North American Sales
- Kathy McGee** VP & General Manager, La Jolla
- Jan Lessem, M.D., Ph.D.** VP & Chief Medical Officer
- Charles E. Hart, Ph.D.** VP & Chief Scientific Officer
- Therésa K. Dixon** VP, Government Affairs & Health Economics

## Board of Directors

- Kevin Rakin (Chairman)** Chief Executive Officer, Advanced BioHealing, Inc.
- Stephen Bloch, M.D.** General Partner, Canaan Partners
- David R. Dantzker, M.D.** General Partner, Wheatley MedTech Partners
- Gary J. Kurtzman, M.D.** VP & Managing Director, Safeguard Scientifics, Inc.
- Carol D. Winslow** Founder & Principal, Channel Medical Partners
- Susan K. Barnes** Former Chief Financial Officer, Intuitive Surgical

## Quick Facts

ABH was founded in 2003 and is a privately held, fully-integrated profitable regenerative medicine company.

## Marketed Products

Dermagraft for the treatment of diabetic foot ulcers

## Development Pipeline

Dermagraft for the treatment of venous leg ulcers  
Dermagraft for application in orthopedic soft tissue repair

## Company Locations

Westport, CT (corporate offices)  
Brentwood, TN (offices and research laboratory)  
La Jolla, CA (manufacturing and operations)

## Employees


As of Q2 2010, ABH has more than 300 employees worldwide.

## Manufacturing Capabilities

The ABH state-of-the-art manufacturing facility is located in La Jolla, California. When operating at maximum capacity, this 70,000 square-foot facility can produce over 250,000 units of Dermagraft per year.

## Research & Development

ABH's lead development program is focused on evaluating Dermagraft for the treatment of venous leg ulcers. This multicenter, international trial has begun. The Company has also initiated a development program focused on utilizing Dermagraft in orthopedic soft tissue repair.



General Customer Service 1.877.4abh.info 1.877.422.4463	Corporate Offices 36 Church Lane Westport, CT 06880	Brentwood Offices 214 Overlook Circle Brentwood, TN 37027	Manufacturing & Operations 10933 N. Torrey Pines Road La Jolla, CA 92037	Corporate Website www.abh.com	Product Websites www.Dermagraft.com www.Heal2gether.org
---	---	---	--	----------------------------------	---

**Delivering the Promise of Regenerative Medicine Today.**

